This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. – 4. (Canceled)

5. (Currently Amended) A method for treating obesity in a subject ranging from 6 to 18 years old and having type 2 diabetes comprising administering to the subject a pharmaceutical composition comprising an effective amount of pramipexole, optionally used in the form of an enantiomer or mixtures of enantiomers thereof, optionally in the form of a pharmacologically acceptable acid addition salt thereof and optionally in the form of a hydrate, solvate or physiologically acceptable salt thereof.

6. – 8. (Canceled)

9. (Currently Amended) The method according to claim 5 ~~claim 8 wherein the pramipexol optionally in the form of its enantiomers, optionally in the form of the pharmacologically acceptable acid addition salts and optionally in the form of the hydrates and solvates or the physiologically acceptable salts thereof is combined with~~ further comprising administering to the subject one or more other active substances selected from the group consisting of the dopamine-D1, D2, D3 or D4 agonists, anorectics, lipase inhibitors and

sympathomimetics.

10. (Original) The method according to claim 5 comprising continuous administration of the composition to the subject.

11. (Original) The method according to claim 10 wherein the continuous administration comprises transdermal administration.

12. (New) The method according to claim 5 wherein the subject ranges from 12 to 18 years old.

13. (New) The method according to claim 5 wherein the subject has a BMI above the 90th percentile.

14. (New) The method according to claim 5 wherein the subject is given a daily dose of 0.005 to 0.02 mg of pramipexole per kg of body weight.

15. (New) The method according to claim 5 wherein the subject has a BMI above the 97th percentile.

16. (New) The method according to claim 5 wherein the subject is given a daily dose of about 0.1 mg of pramipexole per kg of body weight.

17. (New) The method according to claim 5 wherein the isolated (-)-enantiomer of pramipexole is administered to the subject.

18. (New) The method according to claim 5 wherein the subject is given a daily dose of 0.05 to 3 mg per day of pramipexole, based on the free base form.

19. (New) The method according to claim 5 wherein the subject is given a daily dose of 0.1 to 1.5 mg per day of pramipexole, based on the free base form.